CAR T Therapy For Aggressive Childhood T Cell Leukemia
CAR T therapy has yet to be translated for T cell derived leukemias. One study leaves room for hope, as their CAR T product demonstrates early proof-of-concept.
Source: forbes.com
Page 34 - Crispr News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Crispr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Crispr Today - Breaking & Trending Today
US Watchdog Lifts Price Estimate for Gene Therapies
An influential US drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio for sickle cell disease.
Source: medscape.com
CRISPR Technology Market to Reach US$ 7.72 Billion by 2030: Coherent Market Insights
According to Coherent Market Insights, global CRISPR technology market is generated $2.25 billion in 2022, and is anticipated to generate $7.72 billion by 2030,
Source: einnews.com
Stem Cell-Derived CAR T Cells Open Door To Universal Donor Cell Lines
Induced pluripotent stem cells (iPSC), a continuing muse in cell therapy research, could potentially be used to improve flaws associated with conventional CAR T therapy.
Source: forbes.com
The high cost of CRISPR therapy will stop it getting to most patients
The world’s first CRISPR therapy may be approved soon, but sadly it is unlikely to be affordable for hundreds of thousands of people whose pain it could end
Source: newscientist.com